Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Antibody-Chemo combo shows promise in slowing stomach cancer

NCT ID NCT03504397

Disease control Sponsor: Astellas Pharma Global Development, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether adding zolbetuximab, an antibody that targets the Claudin 18.2 protein found on many stomach tumors, to standard chemotherapy can delay cancer progression in people with advanced stomach or gastroesophageal junction cancer. About 565 adults whose cancer has spread and cannot be surgically removed will receive either zolbetuximab plus chemo or a placebo plus chemo. The study is double-blind, so neither patients nor doctors know who gets the active drug. The main goal is to see if the combination extends the time before the cancer worsens.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
zolbetuximab (a targeted antibody) plus chemotherapy (mFOLFOX6)
What this could lead to
If successful, this could provide a new first-line treatment option for people with advanced stomach or GEJ cancer that has a specific protein (Claudin 18.2), potentially slowing cancer growth and extending survival.
What could go wrong
This is an early-stage Phase 3 trial, and results may not confirm benefit. The treatment requires ongoing chemotherapy and may cause side effects like infusion reactions or gut issues. It is not a cure, and patients will still need long-term management.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

565 people

The number who actually took part.

Started

Jun 2018

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female subject eligible to participate if she is not pregnant (negative serum pregnancy test at screening; female subjects with elevated serum beta human chorionic gonadotropin and a demonstrated non-pregnant status through additional testing are eligible) and at least one of the following conditions applies: * Not a woman of child-bearing potential (WOCBP) OR * WOCBP who agrees to follow the contraceptive guidance throughout the treatment period and for at least 9 months after the final administration of oxaliplatin and 6 months after the final administration of all other study drugs * Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 6 months after the final study drug administration. * Female subject must not donate ova starting at screening and throughout the study period, and for 9 months after the final administration of oxaliplatin and 6 months after the final administration of all other study drugs. * A sexually active male subject with a female partner(s) who is of child-bearing potential must agree to use contraception during the treatment period and for at least 6 months after the final study drug administration. * Male subject must agree not to donate sperm starting at screening and throughout the study period, and for 6 months after the final study drug administration. * Male subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or time partner is breastfeeding throughout the study period and for 6 months after the final study drug administration. * Subject has histologically confirmed diagnosis of Gastric or GEJ adenocarcinoma. * Subject has radiologically confirmed locally advanced unresectable or metastatic disease within 28 days prior to randomization. * Subject has radiologically evaluable disease (measurable and/or non-measurable disease according to RECIST 1.1), per local assessment, ≤ 28 days prior to randomization. For subjects with only 1 evaluable lesion and prior radiotherapy ≤ 3 months before randomization, the lesion must either be outside the field of prior radiotherapy or have documented progression following radiation therapy. * Subject's tumor expresses CLDN18.2 in ≥ 75% of tumor cells demonstrating moderate to strong membranous staining as determined by central immunohistochemistry (IHC) testing. * Subject has a HER2-Negative tumor as determined by local or central testing on a gastric or GEJ tumor specimen. (Unique to China: Subject has a known HER2-negative gastric or GEJ tumor.) * Subject has ECOG performance status 0 to 1. * Subject has predicted life expectancy ≥ 12 weeks. * Subject must meet all of the following criteria based on the centrally or locally analyzed laboratory tests collected within 14 days prior to randomization. In the case of multiple sample collections within this period, the most recent sample collection with available results should be used to determine eligibility. * Hemoglobin (Hgb) ≥ 9 g/dL. Subjects requiring transfusions are eligible if they have a post-transfusion Hgb ≥ 9 g/dL. * Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L * Platelets ≥ 100 x 10\^9/L * Albumin ≥ 2.5 g/dL * Total bilirubin ≤ 1.5 x upper limit of normal (ULN) without liver metastases (or \< 3.0 x ULN if liver metastases are present) * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN without liver metastases (or ≤ 5 x ULN if liver metastases are present) * Estimated creatinine clearance ≥ 30 mL/min * Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) ≤ 1.5 x ULN (except for subjects receiving anticoagulation therapy) Exclusion Criteria: * Subject has received prior systemic chemotherapy for locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma. However, subject may have received either neo-adjuvant or adjuvant chemotherapy, immunotherapy or other systemic anticancer therapies, as long as it was completed at least 6 months prior to randomization. Subject may have received treatment with herbal medications that have known antitumor activity \> 28 days prior to randomization. * Subject has received radiotherapy for locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma ≤ 14 days prior to randomization and has not recovered from any related toxicity. * Subject has received systemic immunosuppressive therapy, including systemic corticosteroids within 14 days prior to randomization. Subjects using a physiologic replacement dose of hydrocortisone or its equivalent (defined as up to 30 mg per day of hydrocortisone or up to 10 mg per day of prednisone), receiving a single dose of systemic corticosteroids or receiving systemic corticosteroids as premedication for radiologic imaging contrast use are allowed. * Subject has received other investigational agents or devices within 28 days prior to randomization. * Subject has prior severe allergic reaction or intolerance to known ingredients of zolbetuximab or other monoclonal antibodies, including humanized or chimeric antibodies. * Subject has known immediate or delayed hypersensitivity, intolerance or contraindication to any component of study treatment. * Subject has prior severe allergic reaction or intolerance to any component of mFOLFOX6. * Subject has known dihydropyrimidine dehydrogenase deficiency. * Subject has a complete gastric outlet syndrome or a partial gastric outlet syndrome with persistent/recurrent vomiting. * Subject has significant gastric bleeding and/or untreated gastric ulcers that would exclude the subject from participation. * Subject has a known history of a positive test for human immunodeficiency virus (HIV) infection or known active hepatitis B (positive hepatitis B surface antigen (HBs Ag)) or C infection. NOTE: Screening for these infections should be conducted per local requirements. * For subjects who are negative for HBs Ag, but hepatitis B core antibody (HBc Ab) positive, an HB deoxyribonucleic acid (DNA) test will be performed and if positive, the subject will be excluded. * Subjects with positive hepatitis C virus (HCV) serology, but negative HCV ribonucleic acid (RNA) test are eligible. * Subjects treated for HCV with undetectable viral load results are eligible. * Subject has an active autoimmune disease that has required systemic treatment within the past 3 months prior to randomization. * Subject has active infection requiring systemic therapy that has not completely resolved within 7 days prior to randomization. * Subject has significant cardiovascular disease, including any of the following: * Congestive heart failure (defined as New York Heart Association Class III or IV), myocardial infarction, unstable angina, coronary angioplasty, stenting, coronary artery bypass graft, cerebrovascular accident (CVA) or hypertensive crisis within 6 months prior to randomization. * History of clinically significant ventricular arrhythmias (i.e., sustained ventricular tachycardia, ventricular fibrillation or Torsades de Pointes) * QTc interval \> 450 msec for male subjects; QTc interval \> 470 msec for female subjects * History or family history of congenital long QT syndrome * Cardiac arrhythmias requiring anti-arrhythmic medications (Subject with rate controlled atrial fibrillation for \> 1 month prior to randomization are eligible). * Subject has a history of central nervous system metastases and/or carcinomatous meningitis from gastric/GEJ cancer. * Subject has known peripheral sensory neuropathy \> Grade 1 unless the absence of deep tendon reflexes is the sole neurological abnormality. * Subject has had a major surgical procedure ≤ 28 days prior to randomization. * Subject is without complete recovery from a major surgical procedure ≤ 14 days prior to randomization. * Subject has psychiatric illness or social situations that would preclude study compliance. * Subject has another malignancy for which treatment is required. * Subject has any concurrent disease, infection or comorbid condition that interferes with the ability of the subject to participate in the study, which places the subject at undue risk or complicates the interpretation of data.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Locally advanced unresectable gastric adenocarcinoma or cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

adenocarcinoma gastric adenocarcinoma gastric neoplasm gastroesophageal junction adenocarcinoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Locally advanced unresectable gastric adenocarcinoma or cancer Locally advanced unresectable gastroesophageal junction (GEJ) adenocarcinoma or cancer Metastatic gastric adenocarcinoma or cancer Metastatic gastroesophageal junction (GEJ) adenocarcinoma

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

  • CBCC Global Research, Inc. at Comprehensive Blood and Cancer

    Bakersfield, California, 93309, United States

  • Cancer Treatment Centers of America, Atlanta

    Newnan, Georgia, 30265, United States

  • Cancer Treatment Centers of America, Philadelphia

    Philadelphia, Pennsylvania, 19124, United States

  • City of Hope Nat'l Medical Center

    Duarte, California, 91010, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Earle A. Chiles Research Institute

    Portland, Oregon, 97213, United States

  • Health Partners Institute

    Saint Louis Park, Minnesota, 55426, United States

  • Inova Dwight and Martha Schar Cancer Institute

    Fairfax, Virginia, 22031, United States

  • Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

  • Lancaster General Hospital

    Lancaster, Pennsylvania, 17604, United States

  • Loma Linda University

    Loma Linda, California, 92354, United States

  • Maryland Oncology Hematology

    Brandywine, Maryland, 20613, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114-2696, United States

  • Memorial Cancer Institute - West

    Hollywood, Florida, 33021, United States

  • Memorial Hospital West

    Pembroke Pines, Florida, 33028, United States

  • Memorial Sloan Kettering Cancer Center

    Middletown, Connecticut, 07748-3052, United States

  • Memorial Sloan Kettering Cancer Center

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering Cancer Center

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Cancer Center

    Harrison, New York, 10604, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Cancer Center

    Uniondale, New York, 11553, United States

  • Mount Sinai School of Medicine

    New York, New York, 10029-6574, United States

  • MultiCare Regional Cancer Center - Gig Harbor

    Auburn, Washington, 98801, United States

  • Northwestern University Medical Center

    Chicago, Illinois, 60611, United States

  • Norton Cancer Institute

    Louisville, Kentucky, 40217, United States

  • Oregon Health & Science University

    Portland, Oregon, 97239, United States

  • Orlando Health Inc

    Orlando, Florida, 32806, United States

  • Pacific Shores Medical Group

    Huntington Beach, California, 92648, United States

  • Precision Cancer Research -Dayton Physicians Network

    Middletown, Ohio, 45042, United States

  • Regions Hospital

    Saint Paul, Minnesota, 55101, United States

  • Rhode Island Hospital-Lifespan Cancer Institute

    Providence, Rhode Island, 02903, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263, United States

  • Sanford Cancer Center

    Sioux Falls, South Dakota, 57104, United States

  • Seattle Cancer Care Alliance

    Seattle, Washington, 98109, United States

  • Site AU61002

    Douglas, Queensland, 4814, Australia

  • Site AU61006

    East Bentleigh, Victoria, 3165, Australia

  • Site AU61007

    Kogarah, 2217, Australia

  • Site AU61008

    Adelaide, South Australia, 5011, Australia

  • Site AU61011

    Tugun, Queensland, 4224, Australia

  • Site BE32001

    Brussels, Bruxelles-Capitale, Région de, 1200, Belgium

  • Site BE32002

    Brussels, Liege, 1050, Belgium

  • Site BE32004

    Brussels, 1000, Belgium

  • Site BE32005

    Bruges, 8310, Belgium

  • Site BE32006

    Leuven, Vlaams Brabant, 3000, Belgium

  • Site BE32007

    Edegem, Antwerpen, 2650, Belgium

  • Site BE32008

    Mons, Hainaut, 7000, Belgium

  • Site BE32010

    Haine-Saint-Paul, 7100, Belgium

  • Site BE32011

    Charleroi, 6000, Belgium

  • Site BE32012

    Ghent, Oost-Vlaanderen, 9000, Belgium

  • Site BR55002

    Itajaí, Santa Catarina, 88301-220, Brazil

  • Site BR55003

    Santo André, São Paulo, 09060-650, Brazil

  • Site BR55004

    São Paulo, 08270-070, Brazil

  • Site BR55005

    São José do Rio Preto, São Paulo, 15090-000, Brazil

  • Site BR55006

    Lajeado, Rio Grande do Sul, 95900000, Brazil

  • Site BR55007

    Barretos, São Paulo, 14784-400, Brazil

  • Site BR55009

    São Paulo, 01509-900, Brazil

  • Site BR55010

    Brasília, Federal District, 70200-730, Brazil

  • Site BR55015

    Rio de Janeiro, 22793-080, Brazil

  • Site BR55016

    Passo Fundo, 99010-260, Brazil

  • Site BR55017

    Belo Horizonte, 30130-090, Brazil

  • Site BR55018

    Santa Catarina, 88501-003, Brazil

  • Site CA15002

    Montreal, Quebec, H3T 1M5, Canada

  • Site CA15005

    Edmonton, Alberta, T6G 1Z2, Canada

  • Site CA15008

    Montreal, Quebec, H4A 3J1, Canada

  • Site CA15009

    Saint John, New Brunswick, E2L 4L4, Canada

  • Site CA15011

    Toronto, Ontario, M5G 1X5, Canada

  • Site CL56003

    Providencia, Santiago Metropolitan, 7500921, Chile

  • Site CL56005

    Santiago, 8330032, Chile

  • Site CL56007

    Valdivia, 5090000, Chile

  • Site CL56008

    Providencia, 7520378, Chile

  • Site CN86001

    Xiamen, China

  • Site CN86002

    Beijing, 100071, China

  • Site CN86003

    Haerbin, Heilongjiang, 150081, China

  • Site CN86004

    Hangzhou, Zhejiang, 310003, China

  • Site CN86005

    Hefei, 230022, China

  • Site CN86006

    Nanjing, Jiangsu, 210008, China

  • Site CN86008

    Zhengzhou, 450000, China

  • Site CN86009

    Beijing, 100030, China

  • Site CO57001

    Cali, Colombia

  • Site CO57002

    Medellín, 0574, Colombia

  • Site CO57005

    Cali, Valle del Cauca Department, Colombia

  • Site CO57006

    Medellín, Antioquia, 574, Colombia

  • Site CO57007

    Montería, Departamento de Córdoba, 230002, Colombia

  • Site CO57009

    Bogotá, DC, 110231, Colombia

  • Site DE49002

    Mainz, Rhineland-Palatinate, 55101, Germany

  • Site DE49004

    Leipzig, Saxony, 04103, Germany

  • Site DE49007

    München, Bavaria, 81925, Germany

  • Site DE49008

    Munich, Bavaria, 81377, Germany

  • Site DE49010

    Dresden, Saxony, 01307, Germany

  • Site DE49011

    Berlin, 13353, Germany

  • Site DE49012

    Berlin, 13125, Germany

  • Site DE49015

    Magdeburg, Saxony-Anhalt, 39104, Germany

  • Site DE49018

    Dresden, 1067, Germany

  • Site DE49019

    Heilbronn, 74078, Germany

  • Site DE49021

    Halle, Saxony-Anhalt, 06108, Germany

  • Site ES34003

    Murcia, 30120, Spain

  • Site ES34004

    Madrid, 28034, Spain

  • Site ES34005

    Barcelona, 08003, Spain

  • Site ES34006

    Zaragoza, 50009, Spain

  • Site ES34008

    Madrid, 28007, Spain

  • Site ES34010

    Ávila, Castille and León, 05004, Spain

  • Site ES34011

    Alcorcón, Madrid, 28925, Spain

  • Site ES34013

    Badalona, Barcelona, 08028, Spain

  • Site ES34015

    Barcelona, 08035, Spain

  • Site ES34016

    Barcelona, 08025, Spain

  • Site ES34017

    Madrid, 28033, Spain

  • Site ES34018

    Seville, 41009, Spain

  • Site ES34019

    Burgos, 09006, Spain

  • Site FR33001

    Rennes, Brittany Region, 35042, France

  • Site FR33002

    Paris, Paris, 75970, France

  • Site FR33003

    Lyon, Rhone, 69008, France

  • Site FR33005

    Nice, Provence-Alpes-Côte d'Azur Region, 06200, France

  • Site FR33006

    Poitiers, Vienne, 86021, France

  • Site FR33007

    Nice, 06189, France

  • Site FR33008

    Besançon, Franche-Comte, 25033, France

  • Site FR33009

    Dijon, Bourgogne-Franche-Comté, 21079, France

  • Site FR33010

    Brest, Brittany Region, 29609, France

  • Site FR33011

    Montpellier, Languedoc-Roussillon, 34298, France

  • Site FR33101

    Saint-Herblain, Pays de la Loire Region, 44805, France

  • Site FR33103

    Créteil, 94000, France

  • Site FR33104

    Saint-Priest-en-Jarez, 42270, France

  • Site GB44001

    Manchester, M20 4BX, United Kingdom

  • Site GB44002

    London, NW1 2PG, United Kingdom

  • Site GB44003

    Aberdeen, Aberdeenshire, AB25 2ZN, United Kingdom

  • Site GB44004

    London, W1G 6AD, United Kingdom

  • Site GB44008

    Leeds, LS7 9TF, United Kingdom

  • Site GB44009

    Coventry, CV2 2DX, United Kingdom

  • Site GB44101

    London, London, City of, SW3 6JJ, United Kingdom

  • Site GB44102

    Sutton, Surrey, SM2 5PT, United Kingdom

  • Site GB44103

    Cambridge, CB2 0QQ, United Kingdom

  • Site GB44104

    Dundee, DD2 4BF, United Kingdom

  • Site IL97201

    Haifa, 3109601, Israel

  • Site IL97202

    Jerusalem, 91031, Israel

  • Site IL97203

    Tel Aviv, 64239, Israel

  • Site IL97206

    Kfar Saba, Central District, 44281, Israel

  • Site IL97209

    Holon, 58100, Israel

  • Site IL97210

    HaDarom, 7030000, Israel

  • Site IT39003

    Piacenza, 29100, Italy

  • Site IT39004

    Bergamo, 24127, Italy

  • Site IT39006

    Milan, 20132, Italy

  • Site IT39008

    Milan, 20141, Italy

  • Site IT39009

    Cremona, 26100, Italy

  • Site IT39011

    Meldola, Forli, 47014, Italy

  • Site IT39012

    Parma, 43126, Italy

  • Site IT39013

    Ancona, 60126, Italy

  • Site IT39015

    Roma, 00128, Italy

  • Site IT39016

    Padova, 35128, Italy

  • Site IT39018

    Perugia, 05100, Italy

  • Site IT39019

    Pisa, 56126, Italy

  • Site IT39020

    Monza, Lombardy, 20052, Italy

  • Site IT39021

    Modena, 41124, Italy

  • Site IT39022

    Reggio Emilia, 42123, Italy

  • Site IT39023

    Vicenza, VI, 36100, Italy

  • Site IT39024

    Turin to, 5-10126, Italy

  • Site IT39026

    Terni, 5100, Italy

  • Site JP81001

    Suita, Osaka, Japan

  • Site JP81002

    Matsuyama, Ehime, Japan

  • Site JP81003

    Kashiwa, Chiba, Japan

  • Site JP81004

    Osaka, Japan

  • Site JP81005

    Fukuoka, Japan

  • Site JP81006

    Chuo-ku, Tokyo, Japan

  • Site JP81007

    Sapporo, Hokkaido, Japan

  • Site JP81008

    Koto-ku, Tokyo, Japan

  • Site JP81009

    Nagoya, Aichi-ken, Japan

  • Site JP81010

    Kitaadachi-gun, Saitama, Japan

  • Site JP81011

    Osaka, Japan

  • Site JP81012

    Sunto-gun, Shizuoka, Japan

  • Site JP81013

    Bunkyo-ku, Tokyo, Japan

  • Site JP81014

    Kobe, Hyōgo, Japan

  • Site JP81015

    Hidaka, Saitama, Japan

  • Site KR82002

    Seongnam-si, Gyeonggi-do, 13620, South Korea

  • Site KR82003

    Seoul, 03080, South Korea

  • Site KR82004

    Seoul, Seoul Teugbyeolsi, 06351, South Korea

  • Site KR82005

    Seoul, 05505, South Korea

  • Site KR82006

    Seoul, 6591, South Korea

  • Site KR82007

    Seoul, 152-703, South Korea

  • Site KR82008

    Incheon, 21556, South Korea

  • Site KR82009

    Suwon, Gyeonggido [Kyonggi-do], 16247, South Korea

  • Site MX52001

    Aguascalientes, 20230, Mexico

  • Site MX52002

    Mexico City, Mexico City, 06760, Mexico

  • Site MX52003

    Distrito Federal, 06720, Mexico

  • Site MX52004

    Oaxaca City, Mexico

  • Site MX52007

    Mexico City, Mexico City, 3100, Mexico

  • Site MX52008

    San Luis de Potosi, 78250, Mexico

  • Site MX52009

    Jalisco, 45030, Mexico

  • Site MX52010

    Veracruz, Ver, Veracruz, 91900, Mexico

  • Site PE51001

    Lima, L27, Peru

  • Site PE51003

    Arequipa, 4001, Peru

  • Site PE51004

    San Isidro, Lima region, L27, Peru

  • Site PE51005

    Lima, 15036, Peru

  • Site PE51006

    Lima, 15072, Peru

  • Site PL48002

    Brzozów, Podkarpackie Voivodeship, 36-20, Poland

  • Site PL48004

    Lublin, Lubusz Voivodeship, 20-090, Poland

  • Site PL48005

    Wieliszew, Masovian Voivodeship, 05-135, Poland

  • Site PL48007

    Ostrołęka, Masovian Voivodeship, 07-410, Poland

  • Site PL48009

    Warsaw, 02-781, Poland

  • Site TW88601

    Taipei, 112, Taiwan

  • Site TW88603

    Taichung, 404, Taiwan

  • Site TW88604

    Kaohsiung City, 833, Taiwan

  • Site TW88605

    Kwei-Shan, Taoyuan, 333, Taiwan

  • Site TW88606

    Taipei, 10002, Taiwan

  • Site TW88607

    Tainan, 704, Taiwan

  • Site TW88608

    Kaohsiung City, 80756, Taiwan

  • St. Jude Hospital Yorba Linda

    Fullerton, California, 92835, United States

  • Stony Brook University Medical Center

    Stony Brook, New York, 11794-9452, United States

  • The Angeles Clinic and Research Institute

    Los Angeles, California, 90025, United States

  • The Ohio State University Medical Center

    Columbus, Ohio, 43210, United States

  • The University of Arizona Medical Center

    Tucson, Arizona, 85724, United States

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Thomas Jefferson University

    Philadelphia, Pennsylvania, 19107, United States

  • University of Arizona

    Phoenix, Arizona, 85004, United States

  • University of California - San Francisco

    San Francisco, California, 94143, United States

  • University of California Davis

    Sacramento, California, 95817, United States

  • University of Chicago

    Chicago, Illinois, 60637, United States

  • University of Colorado

    Aurora, Colorado, 80045, United States

  • University of Maryland Medical Center(UMMC)Transplant Center

    Baltimore, Maryland, 21201, United States

  • University of Miami

    Miami, Florida, 33136, United States

  • University of Oklahoma Health Science Center

    Oklahoma City, Oklahoma, 73104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.